Bristol-Myers Squibb Company - BMY -Isin US1101221083

[nobody]

BMY announced a cash dividend of 0.60 with an ex-date of Jan. 4, 2024

[nobody]

Bristol Myers to pay US$800m up front to Chinese drugmaker to develop cancer drug

(Dec 12): Bristol Myers Squibb said on Monday it will pay US$800 million (RM3.74 billion) up front and up to US$8.4 billion to a unit of Sichuan Biokin Pharmaceutical Co to develop and commercialise one of its cancer treatments outside China.

Under the terms of the agreement, SystImmune will be solely responsible for development and commercialisation of the drug in mainland China, while Bristol Myers outside the country.

Bristol Myers said it will pay SystImmune up to US$500 million in contingent near-term payments to co-develop an antibody-drug conjugate that it said has shown promise with a range of solid tumors, including non-small cell lung cancer and breast cancer.

SystImmune will be eligible for additional payments of up to US$7.1 billion contingent upon the achievement of certain development, regulatory and sales performance milestones.

https://theedgemalaysia.com/node/693503

[nobody]

Bristol Myers Squibb to buy Karuna Therapeutics for $14bn

Biopharmaceuticals giant Bristol Myers Squibb has announced it is spending $14bn to purchase Karuna Therapeutics, which develops treatments for people living with psychiatric and neurological conditions.

BMS is paying $330 per share, a 53% premium to Thursday's closing price of $215.19, as it looks to take control of the Karuna's experimental schizophrenia treatment.

Including Karuna's $1.3bn of cash on hand, the net acquisition cost is reduced to $12.7bn. The deal was unanimously approved by the boards of both groups.

Karuna's lead asset, KarXT, is currently awaiting potential government approval for the treatment of schizophrenia in adults, but is also in development for other conditions related to Alzheimer's and bipolar disorder.

According to Mizuho Securities analysts cited by Dow Jones, KarXT's annual sales could exceed $6bn if it is approved for all its potential uses.

“There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space. We expect KarXT to enhance our growth through the late 2020s and into the next decade,” said BMS chief executive Christopher Boerner in a statement.

"This transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need."

The move follows AbbVie's 6 December acquisition of neuroscience drugmaker Cereval Therapeutics for $8.7bn, as the industry's bigger players battle to get their hands on potentially lucrative central nervous system treatments.

https://www.sharecast.com/news/internat ... 83462.html

[charel01]

Farmabedrijf Bristol Myers Squibb sluit tweede miljardendeal in week


Bristol Myers Squibb neemt het Californische RayzeBio over. Het is de tweede keer in een week dat het Amerikaanse farmaconcern miljarden op tafel legt.

Ongeveer 4,1 miljard dollar (ruim 3,7 miljard euro). Zoveel legt Bristol Myers Squibb (BMS) op tafel om RayzeBio over te kopen. Het bedrijf dat zich richt op kankergeneesmiddelen heeft met RYZ101 een middel in de laatste klinische fase. RayzeBio werkt aan geneesmiddelen die via radioactieve deeltjes kankercellen doden en tegelijk moleculen afgeven die zich aan de tumoren hechten.


Farmabedrijven zijn almaar meer geïnteresseerd in medicijnen die zich zeer precies richten op tumoren, terwijl de omringende weefsels relatief ongedeerd blijven.

Dat BMS zijn positie in de kankergeneesmiddelen al te graag wil versterken blijkt uit het bod van 62,5 dollar per aandeel RayzeBio. Dat is meer dan het dubbele van de slotkoers van 30,57 dollar van het bedrijf vrijdag.

Schizofrenie

Het is de tweede miljardendeal van BMS-topman Chris Boerner in korte tijd. Vorige week betaalde BMS 14 miljard dollar voor Karuna Therapeutics, een ontwikkelaar van schizofreniegeneesmiddelen. BMS legt via de deal de hand op het antipsychoticum KarXT, het kroonjuweel van Karuna Therapeutics. Die kandidaat-behandeling voor schizofrenie staat dicht bij een cruciale Amerikaanse goedkeuring. Het middel kon in de derde en laatste klinische testfase goede resultaten voorleggen.


Volgens analisten zou KarXT een jaarverkoop van meer dan 6 miljard dollar kunnen genereren als het middel mettertijd voor meerdere ziektebeelden ingezet kan worden, zoals ook voor alzheimerpatiënten die aan psychose lijden. Het middel is in ontwikkeling voor diverse aandoeningen en wordt ook getest als aanvulling op bestaande schizofreniebehandelingen.

Via de deal wil BMS zijn inspanningen in het veld van de neurowetenschappen versnellen. Daarnaast moet het farmabedrijf nieuwe inkomsten aanboren nu de best verkopende twee producten, de kankerbehandeling Opdivo en de bloedverdunner Eliquis, het einde van hun patentbescherming naderen.
Bron:"De Tijd"

[nobody]

Is Bristol-Myers Squibb a Buy Now? BMY Stock Analysis

Global Value

In this video, we'll perform a BMY stock analysis and figure out what Bristol-Myers Squibb looks like based on the numbers.

We'll also try to figure out what a reasonable fair intrinsic value is for Bristol-Myers Squibb.

And answer is Bristol-Myers Squibb one of the best stocks to buy at the current price?

[nobody]

Bristol Myers posts better-than-expected 4th-quarter results

(Reuters) -Drugmaker Bristol Myers Squibb on Friday posted better-than-expected results for the fourth quarter as sales of its new anemia drug Reblozyl and its already off patent blood cancer drug Revlimid outperformed Wall Street forecasts.

Shares of the New Jersey-based company rose 3.5% to $50.36 in premarket trading.

The company, which announced a string of deals to restock its pipeline late last year, said its revenue was $11.48 billion in the fourth quarter. Analysts, on average, had expected revenue of $11.19 billion, according to LSEG data.

It said it earned $3.5 billion, or $1.70 a share, in the quarter, excluding certain one-time items, also ahead of analyst expectations of $1.53 a share.

Sales of Revlimid were $1.45 billion and Reblozyl were $320 million in the quarter, compared with analyst estimates of $1.27 billion and $280 million, respectively.

The company said it expects 2024 revenue to increase by single digit percentages from 2023, when total revenue was $45 billion. It expects its 2024 reported earnings in the range of $7.10 to $7.40 a share. Analysts, on average had forecast 2024 earnings of $7 a share.

Bristol Myers' Chief Executive Chris Boerner ascended to that position in November right after the company pared back expectations for its existing new product portfolio.

He quickly inked a $14.1 billion deal to buy antipsychotic medicine maker Karuna Therapeutics as well as a $4.1 billion buyout of cancer drugmaker RayzeBio. Those deals followed a $5.8 billion deal in early October for another cancer company, Mirati, which closed last month.

"We did take a number of actions in the fourth quarter that will strengthen the company for long term sustainable growth, and we're certainly working to accelerate the opportunities that we have in our hands today," Chief Commercialization Officer Adam Lenkowsky said in an interview.

Bristol Myers expects to see lower sales later this decade for two of its top selling drugs, cancer immunotherapy Opdivo and blood thinner Eliquis, as they lose patent protection. Sales of Opdivo were $2.39 billion in the quarter, while Eliquis sales were $2.87 billion.

It has already been under pressure from generic competition for Revlimid, once its top-selling drug.

(Reporting by Michael Erman in New York and Bhanvi Satija in Bengaluru; Editing by Sonali Paul)

https://finance.yahoo.com/news/bristol- ... 34539.html

[nobody]

BMY announced a cash dividend of 0.60 with an ex-date of Apr. 4, 2024

[quince]

De daggrafiek toont een RSI in de buurt van 30.
.

BMY 1 dag.png

.
De maandgrafiek toont een RSI in de buurt van 35, dichtbij een meerjarig dieptepunt.
En de aandelenkoers heeft de 200-dagenlijn bereikt dus oppassen hoe het verder verloopt.
.

BMY 1 maand.png

[NewB76]

Niettegenstaande een belangrijke pipeline van molecules ( ook in fase 3) is het blijkbaar toch oververkocht .
Misschien te veel overnames ? of te duur betaald ? en dreigend patentverlies !
Te volgen zullen we maar zeggen !
Maar ook Pfizer noteert zwak .